Shopping Cart

Your shopping cart is currently empty

Felbamate

Name: Felbamate
Brand: TargetMol
SKU: T1946
Price: 35 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T1946Cas No. 25451-15-4

Alias W-554, ADD-03055

Felbamate (W-554) is an Anti-epileptic Agent. The physiologic effect of felbamate is by means of Decreased Central Nervous System Disorganized Electrical Activity.

Felbamate

Copy Product Info

😃Good

Purity: 99%

Catalog No. T1946Alias W-554, ADD-03055Cas No. 25451-15-4

Felbamate (W-554) is an Anti-epileptic Agent. The physiologic effect of felbamate is by means of Decreased Central Nervous System Disorganized Electrical Activity.

Pack Size	Price	USA Warehouse	Global Warehouse
5 mg	$35	In Stock	In Stock
10 mg	$57	In Stock	In Stock
25 mg	$116	In Stock	In Stock
50 mg	$186	In Stock	-
100 mg	$278	Inquiry	Inquiry
200 mg	$418	Inquiry	Inquiry
1 mL x 10 mM (in DMSO)	$38	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99%

Color:White

Resource Download

COA

Product Introduction

Felbamate AI Summary

Felbamate demonstrates notable anticonvulsant activity by blocking both clonic and tonic seizures induced by audiogenic stimuli and NMDA in DBA/2 mice. The compound also exhibits high potency in blocking seizures following D-serine pretreatment. Additionally, it shows bioactivity as a potent NR2B receptor inhibitor with significant inhibitory effects on various mutations expressed in Xenopus oocytes and strong binding affinity to different mutant forms. In relation to GABAA receptors, Felbamate has an IC50 of 95.0 nM in displacing [35S]TBPS from rat brain GABAA receptors and shows an Imax value of 18.0%, suggesting interactions that may affect GABAergic neurotransmission. The compound also exhibits excellent solubility in aqueous solutions, with a solubility of 600 µM after 24 hours in 0.1 M phosphate buffer at pH 7.4, indicating good potential for effective formulation and bioavailability. Though it shows some antiviral activities against SARS-CoV-2, including inhibitory activity against the 3CL-Pro protease and viral cytotoxicity in various cell lines, these effects are relatively modest. The compound demonstrates inhibition percentages between 7.68% and 37.11% at 20 µM concentration for the protease and varied inhibition of cytotoxicity. Liver toxicity potential is significant for Felbamate, indicated by a DILI severity score of 7.0 and elevated serum enzyme levels suggesting an impact on liver function. It has been observed to cause minimal motor impairment in rats, with a TD50 greater than 500.0 mg/kg, but also demonstrates protective indices in various models of induced seizures in mice and rats, such as an ED50 of 25.0 mg/kg for maximal electroshock-induced seizures. Furthermore, Felbamate shows complex bioactivities, including roles as an SMN2 splice variant enhancer, activator and inhibitor of human muscle pyruvate kinase, antagonist of various receptors, inhibitor of Cytochrome P450 2D6, and involvement in histone lysine methyltransferase G9a inhibition. It exhibits a range of interactions with various biochemical and cellular pathways, although it also displays moderate to high potential for human intestinal absorption with a log10(%HIA +10) value of 2.0. Overall, while the compound shows promising pharmacological profiles, its therapeutic application may be limited by its potential liver toxicity..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Felbamate (W-554) is an Anti-epileptic Agent. The physiologic effect of felbamate is by means of Decreased Central Nervous System Disorganized Electrical Activity.
Targets&IC50	NMDAR:1.8 mM
Synonyms	W-554, ADD-03055

Chemical Properties

Molecular Weight	238.24
Formula	C₁₁H₁₄N₂O₄
Cas No.	25451-15-4
Smiles	C(COC(N)=O)(COC(N)=O)C1=CC=CC=C1
Relative Density.	1.275 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 23.8 mg/mL (99.9 mM), Sonication is recommended.

Ethanol: 23.8 mg/mL (99.9 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (8.39 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO/Ethanol

	1mg	5mg	10mg	50mg
1 mM	4.1974 mL	20.9872 mL	41.9745 mL	209.8724 mL
5 mM	0.8395 mL	4.1974 mL	8.3949 mL	41.9745 mL
10 mM	0.4197 mL	2.0987 mL	4.1974 mL	20.9872 mL
20 mM	0.2099 mL	1.0494 mL	2.0987 mL	10.4936 mL
50 mM	0.0839 mL	0.4197 mL	0.8395 mL	4.1974 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc